|Year : 2018 | Volume
| Issue : 2 | Page : 178-184
Platelet-rich plasma for the treatment of diabetic foot ulcer: a randomized, double-blind study
Asser A Goda1, Mohamed Metwally2, Ashraf Ewada2, Hossam Ewees1
1 Department of Vascular Surgery, Sohag Faculty of Medicine, Sohag University, Sohag, Egypt
2 Vascular and Endovascular Unit, Al Azhar Faculty of Medicine, Al Azhar University, Cairo, Egypt
|Date of Submission||05-Dec-2017|
|Date of Acceptance||27-Mar-2018|
|Date of Web Publication||30-May-2018|
Asser A Goda
Assistant Professor, House No 45, Flat 12, 15 Street, Sohag 82511
Source of Support: None, Conflict of Interest: None
Background Diabetic foot ulcer is a major complication of diabetes mellitus. Over the recent years, great progress has made in the techniques of wound healing, among which autologous platelet-rich plasma (PRP) has attracted the most substantial attention. Platelets are known to start the wound healing process through the release of locally active growth factors. The evidence from studies of autologous PRP to support its use in wound healing is not robust, and further rigorously designed blinded trials are needed. The aim of the study was to evaluate the efficacy and safety of the autologous PRP for diabetic foot ulcer in a randomized control multicenter double-blind design.
Patients and methods The study included 50 patients with diabetic foot ulcers, who were divided into two groups: PRP and platelet-poor plasma (PPP) groups. The PRP group was treated with autologous PRP in gel form as a dressing. The PPP group was treated with autologous poor plasma as a dressing. The frequency of dressing change for each group was twice weekly.
Results The healing rate of the PRP group was found to be significantly higher than that of the PPP group. The healing rate per week of the PRP group was significantly higher than that of the PPP group. The rate of complete healing was significantly higher in the PRP group than that of the PPP group.
Conclusion Autologous PRP is effective and safe for treatment of diabetic foot ulcer.
Keywords: diabetic foot ulcer, platelet-poor plasma, platelet-rich plasma
|How to cite this article:|
Goda AA, Metwally M, Ewada A, Ewees H. Platelet-rich plasma for the treatment of diabetic foot ulcer: a randomized, double-blind study. Egypt J Surg 2018;37:178-84
|How to cite this URL:|
Goda AA, Metwally M, Ewada A, Ewees H. Platelet-rich plasma for the treatment of diabetic foot ulcer: a randomized, double-blind study. Egypt J Surg [serial online] 2018 [cited 2021 Sep 19];37:178-84. Available from: http://www.ejs.eg.net/text.asp?2018/37/2/178/233588
| Introduction|| |
Diabetes is a major health problem that is currently showing an alarming rise in its prevalence . Diabetic foot ulcer is a major complication of diabetes mellitus, and is the major component of the diabetic foot . Alvarsson et al.  reported that up to 88% of all lower leg amputation is related to diabetic foot ulcer. The goal of the diabetic foot ulcer treatment is to obtain wound closure as expeditiously as possible . Accepted therapeutic objectives and standards of care for diabetic foot ulcers include wound debridement, pressure relief in the wound area, appropriate wound management (e.g. moist wound healing), infection management, ischemia management, medical management of comorbidities, and surgical management as needed . Over the recent years, great progress has been made in the techniques of wound healing, among which autologous platelet-rich gel has attracted the most substantial attention . Platelets are known to start the wound healing process through the release of locally active growth factors ,,,. The growth factors are able to produce granulation tissue and to induce epithelialization by the production of neovessels, attraction of fibroblasts and mesenchymal cells, secretion of collagen fibers, and by proliferation of keratinocytes ,,,. Platelet-rich plasma (PRP) may also curb inflammation by suppressing cytokine release . PRP has also been demonstrated to be of some antimicrobial properties against microorganisms, such as Escherichia More Details coli, MRSA, Candida albicans, and Cryptococcus neoformans . The evidence from studies of autologous PRP to support its use in wound healing is not robust, and further rigorously designed blinded trials are needed .
The aim of the study was to evaluate the efficacy and safety of the autologous PRP for diabetic foot ulcer in a randomized control multicenter double-blind design.
| Patients and methods|| |
This prospective, randomized, controlled, multicenter double-blind study was done in the Vascular Surgery Department of Sohag Faculty of Medicine and Vascular And Endovascular Units in Al Azhar Faculty of Medicine following approval by the Scientific Ethics Committee.
- Type 1 or 2 diabetes controlled by either medication or insulin.
- Presence of a foot ulcer for at least 4 weeks to be considered chronic.
- According to University of Texas Treatment-Based Diabetic Foot Classification System: ulcers included in this study are of grade 1A (wounds without tendon, capsule, or bone involvement, and also without associated infection or ischemia) or grade 1C (wounds without tendon, capsule, or bone involvement, and also, without associated infection but with ischemia). Patients with ischemia are allowed to be included but with ankle-brachial index (ABI) of greater than or equal to 0.6.
- Patient’s blood vessels are noncompressible for ABI testing.
- ABI of less than 0.6.
- Evidence of gangrene in ulcer or on any part of the foot.
- History of peripheral vascular repair within 30 days of randomization.
- Patient has radiographic evidence consistent with diagnosis of acute Charcot foot.
- Patient has known or suspected osteomyelitis.
- Ulcer size area (length–width) of less than 2 cm2.
- Diabetic foot ulcers that are clinically infected.
- Patients having symptoms or signs suggesting general infection (fever, foot pain, hotness, and redness around the ulcer).
- Ulcers that had exposed tendons, ligaments, or bone.
- Patient who is currently receiving or has received radiation or chemotherapy within 3 months of randomization.
- Screening serum albumin level of less than 2.5 g/dl.
- Screening hemoglobin (Hb) of less than 10.5 mg/dl.
- Screening platelet count of less than 100×109/l.
- Patient undergoing renal dialysis, has known immune insufficiency, liver disease, active cancer, nutritional, hematologic, collagen vascular disease, rheumatic disease, or bleeding disorders.
- Patient having inadequate venous access for blood draw.
- Patients who did not complete their follow-up protocol.
This study was performed on 50 patients. The patient provides a written informed consent before enrolment in the study. All eligible patients were randomized into two groups according to the randomization schedule.
Randomization and blinding procedures
The randomization schedule was generated using the SPSS program (SPSS Inc., Chicago, Illinois, USA). The number and the type of dressing are provided to each vascular research center once the eligible case present there.
Each eligible study participant was assigned to one of the wo treatment groups: the PRP group or the platelet-poor plasma (PPP) group by receiving the next available consecutive randomization number and type of dressing according to the randomization schedule.
Each one of the two vascular research centers share in this research by two participating surgeons
The first participating surgeon (blind surgeon) select the eligible patients, prepared all wounds by removing the necrotic tissue, documented the size, site, and grade of the wounds and continued to follow the wounds during the outpatient visits, regarding the wound size. This surgeon was blind to the type of dressing.
The second surgeon (the unblind surgeon) know the number of the study patients and the treatment group of this patient according to an electronically generated randomization schedule. He also knows the type of the applied dressing and prepare dressings for the patients.
- PRP group (25 patients): the wounds in this group were covered with PRP as their dressing protocol.
- PPP group (25 patients): the wounds in this group were covered with PPP as their dressing protocol.
In both groups, surgical debridement of the wounds was done to freshen the wound bed and remove all necrotic tissue debris. The wound site, sizes (length, width, and depth), and grade were documented.
Platelet-rich plasma and platelet-poor plasma preparation
- Less than 20 ml of venous blood was drawn from the patients (depending on the wound size) into a tube containing an anticoagulant, to avoid platelet activation and degranulation.
- Then the blood was centrifuged, the first centrifugation is called ‘soft spin’ (1000 rpm) for 7–10 min which allows the blood separation into three distinct layers:
- At the bottom of the tube, the red blood corpuscles (RBC) constitute 55% of total volume.
- At the top of the tube, the acellular plasma layer is mainly made up of circulating plasmatic molecules (in particular, fibrinogen) and is low in platelets. It is designated PPP and constitutes 40% of the total volume.
- Between the two, there is an intermediate PRP layer (5% of total volume) called the ‘buffy coat’.
- Using a sterile syringe, the PPP, PRP, and some RBCs (i.e. the upper two layers and very minimal ‘unavoidable’ amount of bottom layer) were transferred into another tube without an anticoagulant.
- This tube underwent a second centrifugation (3000 rpm) for 10 min called ‘hard spin.’ This allowed the platelets (PRP) to settle at the bottom of the tube with very few RBCs.
- The acellular plasma (PPP) (80% of the volume) was found on the top.
- Most of the PPP was taken with a syringe and the remaining PRP was left in the tube.
- At the time of application, the remaining PRP was mixed gently with calcium chloride 10% (0.1 ml) in a Petri-dish and left to rest for 10–15 min until the gel was formed.
- PRP group (25 patients): The PRP was applied to the ulcer followed by Vaseline gauze and then sterile dressing. The frequency of change of dressing was twice weekly. The dressing protocol was performed for up to 12 weeks or stopped whenever healing occurred.
- PPP group (25 patients): PPP was applied to the ulcer followed by Vaseline gauze and then sterile dressing. The frequency of change of dressing was twice weekly. The dressing protocol was performed for up to 12 weeks or stopped whenever healing occurred. General rules regarding the use of offloading techniques for the prevention and healing of plantar foot ulcers in diabetic patients are provided by reducing plantar pressure at sites of ulceration.
Follow-up was twice per week for 12 weeks. The rate of healing of the ulcer was carried out by measuring the ulcer’s dimensions (length, width, and depth) using metric tapes at initial visit and at each visit. Laboratory tests were performed for all patients in two groups every 4 weeks until the patients reach the endpoint.
The endpoints of the current analysis were ulcer healing or end of study occurred at completion of the week 12.
Data were analyzed using STATA (StataCorp LLC, College Station, Texas, USA) intercooled version 12.1. Quantitative data were represented as mean and SD. Data were analyzed using Student’s t-test to compare the mean of two groups and paired t-test was used to compare data before and after producers in each group. Qualitative data were presented as number and percentage and compared using either χ2-test or Fisher’s exact test. The P value was considered significant if it was less than 0.05.
| Results|| |
Between July 2016 and January 2017, 50 patients with diabetic foot ulcer met the inclusion criteria and enrolled in the current series in one of the two groups according to the randomization schedule, 25 patients in each group.
Baseline characteristics of the study patients
There was no significant statistically difference regarding demographic data, risk factors, laboratory parameters, ABI, and wound variables at the baseline for each group which are summarized in [Table 1].
The baseline characteristics of diabetic foot ulcer are shown in [Table 2] and [Figure 1]. The ulcer’s initial length ranged from 2 to 6.5 cm, the initial width ranged from 1.5 to 3.2 cm, the surface area ranged from 4 to 9.6 cm2 with an average of 7.3 cm2, and the volume ranged from 1.2 to 3 cm3 with an average of 1.97 cm3 in the PRP group. The majority of wound sizes in the PRP group (21 out of 25) were in the range of both less than or equal to 7.0 cm2 in area and less than or equal to 2 cm3 in volume. Only four cases in the PRP group had areas of greater than 7 cm2 and a volume of greater than 2 cm3.
The ulcer’s initial length ranged from 2 to 6 cm, the initial width ranged from 1.5 to 3 cm, the surface area ranged from 4 to 9 cm2 with an average of 7.08 cm2, and the volume ranged from 1.4 to 3 cm3 with an average of 1.90 cm3 in the control group. The majority of wound sizes in the control group (23 out of 25) were in the range of less than or equal to 7.0 cm2 in area and less than or equal to 2 cm3 in volume. The remaining two cases in the control group had areas of greater than 7 cm2 and a volume of greater than 2 cm3. There were no statistically significant differences between the two groups regarding average length, width, surface area, and volume.
The ulcer healing rate in the PRP group is significantly faster than the control group. There was statistically significant difference between the PRP group and the control group regarding the ulcer healing rate per week ([Table 3]).
|Table 3 Comparison between the two groups according the healing area over time|
Click here to view
There was statistically significant difference between the PRP group and the PPP group regarding the rate of completely healed ulcer at 10th and 12th weeks; however, the difference was insignificant at the eighth week ([Table 4] and [Table 5], and [Figure 2]).
|Table 4 Comparison between the two groups according to the rate of complete healed ulcer over time|
Click here to view
|Table 5 Comparison of the laboratory investigation between PRP group and control group from the baseline to the endpoint|
Click here to view
There were no statistically significant differences between the PRP group and the PPP group from the baseline to the endpoint laboratory shift in blood picture (Hb and platelet count) and blood chemistry (albumin) ([Table 4]).
| Discussion|| |
This is a prospective, randomized, controlled, double-blind multicenter trial on the use of PRP for the treatment of diabetic foot ulcer. The randomization in this study was generated using the SPSS program and the blindness involves the surgeon who takes the measurements and the patient to provide confidence in the results.
In this study, the majority of wound sizes in the PRP group (21 out of 25) and the PPP group (23 out of 25) were in the range of less than or equal to 7.0 cm2 in area and less than or equal to 2 cm3 in volume. The remaining six cases, four in the PRP group and two in the PPP group, had areas of greater than 7 cm2 and volume of greater than 2 cm3. The results of various studies suggest that a wound size of less than 7.0 cm2 is most common ,,. The average baseline area in the majority of wounds was similar to that reported in many literatures. Driver et al.  reported that the majority of wounds (35 out of 40) met the criteria of wound area of less than or equal to 7.0 cm2 and volume of less than or equal to 2.0 cm3. Lipkin et al.  reported in a tissue-engineered product study in healing of diabetic foot ulcer that ∼70% of the ulcers were less than 6 cm2. Another tissue-engineered product study in healing diabetic foot ulcer was done by Veves et al. . Veves et al.  reported that the average wound size area in the graftskin group that included 112 patients was 2.97±3.10 and in the control group that included 96 patients was 2.83±2.45. In a large study that was done by Margolis et al.  included 26 599 diabetic foot ulcer patients, about 60% of which had an wound area of less than 6 cm2 that matched the majority of wound areas in the current study.
In this study, the ulcer healing rate in the PRP-treated wound group is significantly faster than that in the PPP group (0.66±0.04 vs. 0.49±0.03). This result is similar to that reported in many literatures.
Saad Setta et al.  reported in a randomized trial on the use of PRP on chronic diabetic foot ulcer on 24 patients that the healing of ulcer by PRP is significantly faster than by PPP.
Kakagia et al.  reported in a randomized trial on chronic diabetic foot ulcers of 51 patients that the rate of healing for the combination of PRP and protease-modulating matrix statistical is higher compared with protease-modulating matrix alone.
In 2001, a retrospective controlled study by Margolis et al.  on the use of platelet releasates on diabetic foot ulcer of 26 599 patients showed statistically significant higher rate of healing at 20th week after treatment by platelet releasates (50 vs. 41%; P<0.05).
In 2010, a systematic review and meta-analysis of Villela and Santos  showed that there is scientific evidence regarding favorable outcomes especially the healing rate with the PRP group that reflects the effectiveness of the use of PRP for the treatment of diabetic ulcers.
In this study, the rate of completely healed ulcer in the PRP group was statistically significantly higher than the PPP group at 10th week and at 12th week [11 (44.00%) vs. 1 (4.00%)] and [21(84.00%) vs. 13 (52.00%)] consequently. The result in this study is similar to the result reported by Driver et al. , Ahmed et al. , and Jeong et al. .
Driver et al.  published a randomized double-blind trial on the use of PRP on chronic diabetic foot ulcers and found a statistically significant difference regarding the rate of complete healing after treatment of diabetic foot ulcer by PRP (81.3 vs. 42.1%, P<0.05).
In 2010, the prospective controlled study of Jeong et al.  on 100 patients with chronic diabetic foot ulcers founds a statistically significant higher rate of complete healing (79 vs. 46%, P<0.05) after treatment using blood bank platelet concentrates.
In 2017, Ahmed et al.  published a randomized controlled trial on the use of PRP on diabetic foot ulcer of 56 patients and found a statistical difference regarding the rate of complete healing after treatment by PRP (86 vs. 68%, P<0.05).The periodic laboratory tests that were done for patients in this study to measure Hb, hematocrit, platelet counts, and albumin showed that the frequent small amounts of blood collection (≤20 ml) that was done on each visit did not reduce these blood elements. The result in this study is agreeable with that reported by Driver et al. . Driver et al.  reported that there were no statistically or clinically significant differences noted between the PRP gel and control from baseline to endpoint laboratory shifts in hematology, clotting factors, and factor V tests. Also, Driver et al.  reported that there were no clinical or statistically significant differences in chemistry test for sodium, potassium, chloride, bicarbonate, creatinine, or albumin. Serum glucose or glycosylated hemoglobin results showed that more patients shifted to high at endpoint in the PRP gel compared with the control group. These differences were not statistically significant or clinically meaningful.
| Conclusion|| |
The present study concludes that PRP is effective and safe for treatment of diabetic foot ulcer. PRP is effective where it significantly accelerates healing of diabetic foot ulcer and safe where it does not make significant changes on blood hematology or blood chemistry (albumin) in the patients.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Kontopodis N, Tavlas E, Papadopoulos G, Pantidis D, Kafetzakis A, Chalkiadakis G, Ioannou C. Effectiveness of platelet-rich plasma to enhance healing of diabetic foot ulcers in patients with concomitant peripheral arterial disease and critical limb ischemia. Int J Low Extrem Wounds 2016; 15:45–51.
Tran T, Le P, Pham P. Diabetic foot ulcer treatment by activated platelet rich plasma: a clinical study. Biomed Res Ther 2014; 1:37–42.
Alvarsson A, Sandgren B, Wendel C, Alvarsson M, Brismar K. A retrospective analysis of amputation rates in diabetic patients: can lower extremity amputations be further prevented? Cardiovasc Diabetol 2012; 11:18.
Driver V, Hanft J, Fylling C, Beriou J, and the AutoloGel™ Diabetic Foot Ulcer Study Group. A prospective, randomized, controlled trial of autologous platelet-rich plasma gel for the treatment of diabetic foot ulcers. Ostomy Wound Manag 2006; 52:68–87.
Frykberg RG, Armstrong DG, Giurini J, Edwards A, Kravette M, Kravitz S et al.
Diabetic foot disorders: a clinical practice guideline. Park Ridge, IL: American College of Foot and Ankle Surgeons; 2000.
Yang L, Gao L, Yang LV, Wang J. Autologous platelet-rich gel for lower-extremity ischemic ulcers in patients with type 2 diabetes. Int J Clin Exp Med 2017; 10:13796–13801.
Lacci MK, Dardik A. Platelet-rich plasma: support for its use in wound healing. Yale J Biol Med 2010; 83:1e9.
Marx RE. Platelet-rich plasma (PRP): what is PRP and what is not PRP? Implant Dent 2001; 10:225e8.
Kevy SV, Jacobson MS. Preparation of growth factor enriched autologous platelet gel. Presented at the 27th Annual Meeting of the Society for Biomaterials. St. Paul, MN. 26 April 2001.
Everts PA, BrownMahoney C, Hoffmann JJ, Schönberger JP, Box HA, van Zundert A, Knape JT. Platelet-rich plasma preparation using three devices: implications for platelet activation and platelet growth factor release. Growth Factors 2006; 24:165e71
Yang HS, Shin J, Bhang SH, Shin JY, Park J, Im GI et al.
Enhanced skin wound healing by a sustained release of growth factors contained in platelet-rich plasma. Exp Mol Med 2011; 43:622–629.
Pietramaggiori G, Scherer SS, Mathews JC, Gennaoui T, Lancerotto L, Ragno G et al.
Quiescent platelets stimulate angiogenesis and diabetic wound repair. J Surg Res 2010; 160:169–177.
Pietramaggiori G, Scherer SS, Mathews JC, Alperovich M, Yang H-J., Neuwalder J et al.
Healing modulation induced by freeze-dried platelet-rich plasma and micronized allogenic dermis in a diabetic wound model. Wound Repair Regen 2008; 16:218–225.
Argolo Neto NM, Del Carlo RJ, Monteiro BS, Nardi NB, Chagastelles PC, de Brito AFS et al.
Role of autologous mesenchymal stem cells associated with platelet-rich plasma on healing of cutaneous wounds in diabetic mice. Clin Exp Dermatol 2012; 37:544–553.
Mishra A, Woodall JJr, Vieira A. Treatment of tendon and muscle using platelet-rich plasma. Clin Sports Med 2009; 8:113e25.
Tang YQ, Yeaman MR, Selsted ME. Antimicrobial peptides from human platelets. Infect Immun 2002; 70:6524e33.
Game F, Attinger J, Attinger C, Hartemann A, Hinchliffe A, Löndahl M et al.
Effectiveness of interventions to enhance healing of chronic ulcers of the foot in diabetes: a systematic review. Diabetes Metab Res Rev 2016; 32(Suppl 1):154–168.
Margolis DJ, Kantor J, Berlin J. Healing of diabetic neuropathic foot ulcers receiving standard treatment. Diabetes Care 1999; 22:692–695.
Lee ET. Statistical methods for survival data analysis. Belmont, CA: Lifetime Learning Publications, Wadsworth, Inc; 1980.
Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York, NY: John Wiley and Sons; 1980.
Lipkin S, Chaikof E, Isseroff Z, Silverstein P. Effectiveness of bilayered cellular matrix in healing of neuropathic diabetic foot ulcers: results of a multicenter pilot trial. Wounds 2003; 15:230–236.
Veves A, Falanga V, Armstrong DG, Sabolinski M. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers. Diabetes Care 2001; 24:290–295.
Margolis DJ, Gelfand JM, Hoffstad O, Berlin J. Surroga teendpoints for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2003; 26:1696–1700.
Saad Setta H, Elshahat A, Elsherbiny K, Massoud K, Safe I. Platelet-rich plasma versus platelet-poor plasma in the management of chronic diabetic foot ulcers: a comparative study. Int Wound J 2011; 8:307–312.
Kakagia DD, Kazakos KJ, Xarchas KC, Karanikas M, Georgiadis GS, Tripsiannis G et al.
Synergistic action of protease-modulating matrix and autologous growth factors in healing of diabetic foot ulcers. A prospective randomized trial. J Diabetes Complications 2007; 21:387–391.
Margolis D, Kantor J, Santanna J, Strom B, Berlin J. Effectiveness of platelet releasate for the treatment of diabetic neuropathic foot ulcers. Diabetes Care 2001; 24:483–488.
Villela DL, Santos VLCG. Evidence on the use of plateletrich plasma for diabetic ulcer: a systematic review. Growth Factors 2010; 28:111–116.
Jeong S-H, Han S-K, Kim W-K. Treatment of diabetic foot ulcers using a blood bank platelet concentrate. Plast Reconstr Surg 2010; 125:944–952.
Ahmed M, Reffat SH, Hassan A, Eskander F. Platelet-rich plasma for the treatment of clean diabetic foot ulcers. Ann Vasc Surg 2017; 38:206–211.
[Figure 1], [Figure 2]
[Table 1], [Table 2], [Table 3], [Table 4], [Table 5]